GSK2593074A (Synonyms: GSK'074) |
| Catalog No.GC66479 |
GSK2593074A(GSK'074)는 RIP1과 RIP3 모두에 대한 이중 표적 능력을 가진 괴사 억제제입니다.821d96072c2d58d8970e76f526b0f6b8
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1337531-06-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
GSK2593074A (GSK'074) is a necroptosis inhibitor with dual targeting ability to both RIP1 and RIP3[1].
GSK2593074A (GSK'074; 0.01, 0.1, 1, 10, and 100 nM; 6 hours for MOVAS cells; 3 hours for L929 cells) completely rescues cells from necroptosis under different stimuli in both human and murine cells at IC50~3 nM. In multiple cell types including mouse SMCs, fibroblasts (L929), bone marrow derived macrophages (BMDM), and human colon epithelial cells (HT29), GSK2593074A inhibits necroptosis with an IC50 of ~3 nM[1].
Cell Viability Assay[1]
| Cell Line: | Mouse smooth muscle cell line MOVAS; Mouse fibroblast cell line L929 |
| Concentration: | 0.01, 0.1, 1, 10, and 100 nM |
| Incubation Time: | 6 hours for MOVAS cells; 3 hours for L929 cells |
| Result: | Inhibited MOVAS and L929 cells with the IC50 of 3 nM. |
GSK2593074A (GSK'074; 0.93 mg/kg/day; i.p. injection; 14 or 28 days) is administrated to Apoe-/- mice immediately following pump implantation. Compared to the DMSO group, GSK2593074A-treated mice show significantly alleviated aneurysm formation, reflected by a much smaller aortic dilatation (DMSO 85.39±15.76% vs GSK2593074A 36.28±5.76%; P<0.05) as well as a reduced abdominal aortic aneurysm (AAA) incidence (from 83.3 to 16.7%). GSK2593074A significantly decreases the extent of aortic expansion (DMSO 66.06±9.17% vs GSK2593074A 27.36±8.25%; P<0.05) [1].
| Animal Model: | Apoe-/- female mice (9-10 months)[1] |
| Dosage: | 0.93 mg/kg/day; 200 µL |
| Administration: | Daily i.p. injection; 14 or 28 days |
| Result: | Inhibited aneurysm formation in mouse models of aneurysms. |
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *